Erschienen in:
01.11.2011
Bevacizumab at recurrence in high-grade glioma
verfasst von:
Andrea Salmaggi, Paola Gaviani, Andrea Botturi, Elena Lamperti, Giorgia Simonetti, Daniela Ferrari, Antonio Silvani
Erschienen in:
Neurological Sciences
|
Sonderheft 2/2011
Einloggen, um Zugang zu erhalten
Abstract
Bevacizumab has been introduced in the management of high-grade gliomas after preliminary studies that showed an acceptable safety and a marked increase in clinico-radiological responses in comparison with second-line chemotherapy. The objective is to synthetically review the present use of bevacizumab—alone or in combination—in the context of recurrent high-grade glioma and highlight the future developments. The methodology of this study is to analyse and discuss relevant literature studies using bevacizumab in recurrent high-grade glioma. Bevacizumab may be used as single-agent therapy in recurrent high-grade glioma, with good clinico-radiological responses having little effect on survival. The open questions and developments include new MRI criteria for evaluation of response to anti-angiogenic agents, the identification of putative factors predicting response/failure of bevacizumab and the introduction of bevacizumab in first-line management of high-grade glioma.